Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + nab-paclitaxel + cetuximab
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A three-drug cancer regimen combining the platinum agent carboplatin, the nanoparticle albumin-bound taxane nab-paclitaxel, and the anti-EGFR monoclonal antibody cetuximab. Mechanistically, carboplatin forms DNA crosslinks causing DNA damage and apoptosis; nab-paclitaxel stabilizes microtubules to inhibit mitosis; and cetuximab blocks epidermal growth factor receptor signaling and mediates antibody-dependent cellular cytotoxicity. This combination has been investigated primarily in head and neck squamous cell carcinoma (HNSCC), including as induction therapy for locally advanced disease and as first-line therapy for recurrent or metastatic HNSCC under the CACTUX regimen, showing feasibility and antitumor activity in phase II and institutional studies.
- Other names
- carboplatin plus nab-paclitaxel plus cetuximabCACTUX regimen
02
Targets
Beyond the preview
Go deeper on carboplatin + nab-paclitaxel + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + nab-paclitaxel + cetuximab.